Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Conditions studied
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
About this study
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Interventions
- Drug: ECI830 — Experimental
- Drug: ribociclib — Approved medication
- Drug: fulvestrant — Approved medication
Primary outcomes
- Phase I: Incidence of dose-limiting toxicities (DLTs) (2 years)
- Phase I: Incidence of adverse events (AEs) and serious adverse events (SAEs) (2 years)
- Phase I: Number of participants with dose interruptions, reductions and discontinuations (2 years)
- Phase II: PFS rate at 6 months per local response evaluation criteria in solid tumors (RECIST) v1.1 (6 months)
Eligibility information
Study locations
- University of California LA, Los Angeles, California 90095 United States
- Florida Cancer Specialists, Fort Myers, Florida 33901 United States
- Dana Farber Cancer Institute, Boston, Massachusetts 02115 United States
- WA Uni School Of Med, St Louis, Missouri 63110 United States
- Memorial Sloan Kettering, New York, New York 10017 United States
- SCRI Oncology Partners, Nashville, Tennessee 37203 United States
- MD Anderson Cancer Center Uni of Te, Houston, Texas 77030 United States
- Fred Hutch Cancer Research, Seattle, Washington 98109 United States
- Novartis Investigative Site, Clayton, Victoria 3168 Australia
- Novartis Investigative Site, Melbourne, Victoria 3004 Australia
Showing 10 of 33 reported sites. See the official listing for all locations.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-18.